Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

The graft-versus-tumor effect in pediatric malignancy.

Fry TJ, Willasch A, Bader P.

Pediatr Clin North Am. 2010 Feb;57(1):67-81. doi: 10.1016/j.pcl.2009.12.002. Review.

PMID:
20307712
3.

Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.

Maloney DG.

Leuk Lymphoma. 2003;44 Suppl 3:S99-105. Review.

PMID:
15202532
4.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.

Stelljes M, Strothotte R, Pauels HG, Poremba C, Milse M, Specht C, Albring J, Bisping G, Scheffold C, Kammertoens T, Oelmann E, Silling G, Berdel WE, Kienast J.

Blood. 2004 Aug 15;104(4):1210-6. Epub 2004 Apr 15.

6.
7.

Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.

Stelljes M, Specht C, Albring J, Volkmann S, Schlösser V, Pauels HG, Poremba C, Bisping G, Opitz C, Scheffold C, Silling G, Kiehl M, Berdel WE, Kienast J.

Transplantation. 2007 Feb 15;83(3):314-22.

PMID:
17297406
9.

Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.

Talmadge JE.

Int Immunopharmacol. 2003 Aug;3(8):1121-43. Review.

PMID:
12860168
10.

Cytolytic pathways in haematopoietic stem-cell transplantation.

van den Brink MR, Burakoff SJ.

Nat Rev Immunol. 2002 Apr;2(4):273-81. Review.

PMID:
12001998
11.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH.

Biol Blood Marrow Transplant. 2001;7(4):230-8.

PMID:
11349810
12.

Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.

Mohty M, Fegueux N, Exbrayat C, Lu ZY, Legouffe E, Quittet P, Lopez-Martinez E, Latry P, Avinens O, Hertog C, Klein B, Eliaou JF, Rossi JF.

Bone Marrow Transplant. 2001 Aug;28(4):335-9.

13.

Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.

Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R.

J Clin Oncol. 2004 Oct 1;22(19):3886-92. Epub 2004 Aug 16.

PMID:
15314059
14.

Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.

Ito M, Shizuru JA.

Biol Blood Marrow Transplant. 1999;5(6):357-68.

15.

T cells require TRAIL for optimal graft-versus-tumor activity.

Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon JJ, van den Brink MR.

Nat Med. 2002 Dec;8(12):1433-7. Epub 2002 Nov 11.

PMID:
12426560
16.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
17.

Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.

Espinoza-Delgado I, Childs RW.

Expert Rev Anticancer Ther. 2004 Oct;4(5):865-75. Review.

PMID:
15485320
18.
19.

Reduced-intensity hematopoietic stem cell transplantation (RIST) for solid malignancies.

Kami M, Makimoto A, Heike Y, Takaue Y.

Jpn J Clin Oncol. 2004 Dec;34(12):707-16. Review.

PMID:
15640500
20.

Reduced-intensity allogeneic hematopoietic cell transplantation: Graft versus tumor effects with decreased toxicity.

Schwartz JE, Yeager AM.

Pediatr Transplant. 2003 Jun;7(3):168-78. Review.

PMID:
12756040

Supplemental Content

Support Center